Abstract Body

Presentation:

For this invited talk, the role of inflammation and cardiovascular disease will be reviewed both in the context of the general population and persons living with HIV. In particular, the impact of statin therapy on inflammation as part of the JUPITER (non-HIV) and REPRIEVE (HIV) trials will be compared. Among persons with HIV, proof-of-concept studies have provided insight by probing different targets in the inflammatory cascade. In the general population, anti-inflammatory interventions such as colchicine and canakinumab have significantly reduced clinical events. Differences in immmune-based therapeutics among persons with HIV and the general population will be discussed. Finally, future therapeutic strategies for immunomodulation which may be more relevant in the context of HIV disease pathogenesis will be considered.